Expanded Ceprate Claims Supported by Data, FDA Advisory Committee Agrees
This article was originally published in The Gray Sheet
Executive Summary
CellPro's premarket approval application supplement for the Ceprate SC stem cell concentration system supports use in peripheral blood stem cell concentration and tumor purging, FDA's Biological Response Modifiers Advisory Committee concluded at its March 24 meeting in Rockville, Maryland.